Acutaas Chemicals granted process patent for 2,4-dimethylthiophenol

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Patent granted for 2,4-dimethylthiophenol preparation process
  • Total patents held by company now stand at 11
  • Patent term is 20 years from filing date in 2017
  • Disclosure made under SEBI LODR Regulation 30
powered bylight_fuzz_icon
50591016

*this image is generated using AI for illustrative purposes only.

Acutaas Chemicals received a process patent from the Indian Patent Office on September 10, 2026. The approval covers a method for preparing 2,4-dimethylthiophenol, developed at the company’s internal R&D centre.

The patent is valid for 20 years from the filing date of September 21, 2017. This grant raises Acutaas Chemicals’ total portfolio to 11 patents for innovative processes and technology.

The company disclosed the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was issued to both the BSE and NSE listing departments.

What the Numbers Show

The accumulation of 11 patents indicates a sustained focus on indigenous process innovation. With the latest patent covering a specific chemical preparation method, the company reinforces its technical moat in specialty chemicals.

Historical Stock Returns for Acutaas Chemicals

1 Day5 Days1 Month6 Months1 Year5 Years
+6.47%+10.10%+4.65%+60.19%+129.50%0.0%

How will the commercialization of the 2,4-dimethylthiophenol process impact Acutaas Chemicals' revenue streams in the upcoming fiscal quarters?

Does this new patent provide a significant competitive advantage against global specialty chemical manufacturers, and if so, in which specific end-use industries?

What is the estimated timeline for scaling up production of 2,4-dimethylthiophenol from R&D to full-scale manufacturing?

Acutaas Chemicals inaugurates HPAPI pilot plant in Surat for R&D

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Acutaas Chemicals inaugurated a new pilot plant at Unit 1, Sachin, Surat on September 4, 2026.
  • The facility features OEB 4 containment for handling highly potent API intermediates.
  • It supports R&D for new product trials and process scale-up validation.
  • The expansion targets high-potency APIs used in targeted therapies like oncology.
powered bylight_fuzz_icon
50049982

*this image is generated using AI for illustrative purposes only.

Acutaas Chemicals inaugurated a new pilot plant at its Unit 1 facility in Sachin, Surat, on September 4, 2026. The state-of-the-art facility is designed to support research and development for new product trials and the scale-up of high-potency active pharmaceutical ingredient (API) intermediates.

Facility details

The new plant includes a dedicated area with Occupational Exposure Band (OEB) 4 containment. This infrastructure enables the company to undertake development and validation of highly potent intermediates used in manufacturing high-potency APIs. The facility serves as an intermediate step between laboratory-scale synthesis and full commercial production.

Parameter Details
Inauguration date September 4, 2026
Location Unit 1, Sachin, Surat
Containment standard OEB 4
Primary function R&D and scale-up of HPAPI intermediates

Strategic significance

High-potency APIs are critical components in targeted therapies, including oncology treatments. By establishing a dedicated pilot plant with stringent containment protocols, Acutaas Chemicals signals its intent to build capabilities in this technically demanding segment. The facility allows for process optimisation and scale-up validation before large-scale manufacturing commences.

The company disclosed this development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Acutaas Chemicals

1 Day5 Days1 Month6 Months1 Year5 Years
+6.47%+10.10%+4.65%+60.19%+129.50%0.0%

What is the expected timeline for transitioning products from this pilot plant to full commercial manufacturing?

How might this new OEB 4 capability impact Acutaas Chemicals' revenue mix from high-margin oncology intermediates in the next fiscal year?

Are there any existing partnerships or customer contracts that will specifically leverage this new pilot facility for scale-up validation?

More News on Acutaas Chemicals

1 Year Returns:+129.50%